Evidence map›Paper›PMID 31977148›Full record

ArticleCurrent protocols in stem cell biology2020

Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521.

Christian Skorik, Nathaniel K Mullin, Michael Shi, Yosra Zhang, Phoebe Hunter, Yang Tang, Brianna Hilton, Thorsten M Schlaeger

Open access · greenAbstract read
In one paragraph

Article in Current protocols in stem cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Efficient Generation of Functional TCRαβbioRxiv : the preprint server for biology · 2026
    Article
  3. Advancements in theFrontiers in toxicology · 2025
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Christian SkorikStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Nathaniel K MullinStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Michael ShiStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Yosra ZhangStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Phoebe HunterStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Yang TangStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Brianna HiltonStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Thorsten M SchlaegerStem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Harvard Stem Cell Institute · USBoston Children's Hospital · USHarvard University · USStemcell Technologies · CAUniversity of Iowa · US

Funding

Project-002U54DK110805 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI ORKIN, STUART H, ZON, LEONARD IRA · 2016 to 2020
$5.9M
NIDDK NIH HHS U54 DK110805
6 · The paper itself

Abstract

Translating human induced pluripotent stem cell (hiPSC)-derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component-free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component-free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1 kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSR Plus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent-derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages. © 2020 by John Wiley & Sons, Inc. Basic Protocol 1: Isolating peripheral blood mononuclear cells using CPT tubes Support Protocol 1: Removal of clotting factors to produce serum from autologous plasma collected in Basic Protocol 1 Basic Protocol 2: PBMC expansion in an animal-free erythroblast expansion medium containing autologous serum Basic Protocol 3: Reprogramming of expanded PBMCs with Sendai viral reprogramming particles Alternate Protocol: Reprogramming of expanded PBMCs with episomal plasmids Basic Protocol 4: Picking, expanding, and cryopreserving hiPSC clones Support Protocol 2: Testing Sendai virus kit-reprogrammed hiPSC for absence of Sendai viral RNA Support Protocol 3: Testing Epi5 kit-reprogrammed hiPSC for absence of episomal plasmid DNA Support Protocol 4: Assessing the undifferentiated state of human pluripotent stem cell cultures by multi-color immunofluorescent staining and confocal imaging Support Protocol 5: Coating plates with extracellular matrices to support hiPSC attachment and expansion.

Indexed as

Cellular ReprogrammingCell DifferentiationCell ProliferationClone CellsCryopreservationErythrocytesExtracellular MatrixHumansInduced Pluripotent Stem CellsLamininLeukocytes, MononuclearPlasmidsRNA, ViralSendai virusSerumLamininRNA, Viralepisomal reprogramminghuman induced pluripotent stem cells (hiPSCs)reprogrammingSendai viral reprogramming

Identifiers

PMID31977148
PMCPMC7176073
OpenAlexW3001447444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.